$因塞特(INCY)$ 白癜风特效药要来啦。。效果非常出色啊。24周的时候45.5%的人改善面积超过50%。

52周的时候57.6%的人改善超过50%。其中51.5%改善超过75%。33.3%的人改善超过90%。

A Phase 2 clinical trial evaluating Incyte's (NASDAQ:INCY) ruxolitinib cream in patients with a blotchy skin disorder called vitiligo met the primary endpoint. The results are being presented at the European Academy of Dermatology and Venereology Congress in Madrid.

A statistically significant proportion (45.5%) of treated (1.5% cream twice daily) patients achieved at least a 50% improvement in facial assessment of a scale called F-VASI50 at week 24 compared to vehicle (placebo).

At week 52, the proportion of participants achieving F-FASI50 increased to 57.6%. Also at week 52, 51.5% of patients receiving the 1.5% cream twice daily achieved 75% improvement while 33.3% achieved at least 90% improvement.